Table 1.
Potential diagnostic and prognostic markers of RA among miRNAs.
| Clinical potential | miRNA | Type of sample | Expression | References |
|---|---|---|---|---|
| Diagnostic marker | miRNA-16 | Synovial fluid | Increased, comparing to another autoimmune diseases | Mi et al., 2013 |
| miRNA -223 | Synovial fluid | Increased, comparing to another autoimmune diseases | Shibuya et al., 2013 | |
| miRNA-24, miRNA-30a-5p, miRNA-125a-5p | Plasma | Increased in ACPA-positive and ACPA-negative donors before clinical symptoms appear | Murata et al., 2013 | |
| miRNA-22, miRNA-382, miRNA-486-3p | Whole blood | Increased in ACPA-positive donors before clinical symptoms appear | Ouboussad et al., 2017 | |
| miRNA-10a | Whole blood | Decreased in RA patients | Hong et al., 2018 | |
| miRNA-155 | Serum | Increased in RA patients | Abdul-Maksoud et al., 2017 | |
| miRNA-210 | Serum | Decreased in RA patients | Abdul-Maksoud et al., 2017 | |
| miRNA-26à | Serum/plasma | Increased in RA patients | Murata et al., 2013 | |
| Disease progression | miRNA-146a, miRNA-16, miRNA-150 |
PBMCs | Correlates with disease progression | Filkova et al., 2012 |
| miRNA-16, miRNA-146a, miRNA-155 |
Whole blood | Lower level on early stages, than in advanced disease | Filková et al., 2014 | |
| miRNA-146a | Synovial fluid, blood | Correlates with disease progression | Chung et al., 2016 | |
| miRNA-16 | Plasma | Correlates with disease progression | Murata et al., 2010 | |
| Response to treatment: | ||||
| Adalimumab | miR-22 | Whole blood | Better response to therapy when decreased | Krintel et al., 2016 |
| miR-886-3p | Whole blood | Better response to therapy when increased | Krintel et al., 2016 | |
| Rituximab | miRNA-125b | Serum | Better response to therapy when increased | Duroux-Richard et al., 2014 |
| Methotrexate | miR-10a | Whole blood | Better response to therapy when decreased | Hong et al., 2018 |
| Anti-TNF-α therapy | miR-5196 | Serum | Better response to therapy when increased | Ciechomska et al., 2017 |
| miR-146a-5p | Serum | Better response to therapy when increased | Bogunia-Kubik et al., 2016 | |
| Anti-TNF/DMARD therapy | miR-16-5p, miR-23-3p, miR125b-5p, miR-126-3p, miR-146a-5p, miR-223-3p | Serum | Prognostic panel of therapy efficiency | Castro-Villegas et al., 2015 |
| DMARD therapy and glucocorticoids | miR-16, miR-223 | Serum | Better response to therapy when increased | Filková et al., 2014 |